anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To provide a method for producing a rapidly soluble tablet capable of efficiently producing the tablet by simple processes and suitable for mass production and to obtain a rapidly soluble tablet by the method. CONSTITUTION: This rapidly soluble tablet is produced by a compression process, a wetting process and a drying process. In the compression process, tablet materials in a dry state containing a pharmaceutical agent, a water-soluble binder and a water-soluble excipient are compressed with a minimum pressure necessary for producing tablets having hardness which is sufficient for keeping the shapes of the tablets while they are transferred to the next production process. In the wetting process, the tablets are subjected to a specific wetting treatment. In the drying process, the wet tablets are dried to remove water. These processes enable that tablets having sufficiently rapid solubility are produced and the solubility is kept through the processes while keeping excellent productivity in the compression process.  Further, the obtained tablets have sufficient tablet hardness necessary for circulation and for using by a user owing to a function of enhancing the hardness of the binder in the wetting process and the drying process.
RESEARCH QUESTION: What is the contribution of sociodemographic, psychosocial, lifestyle and reproductive factors up to the age of 11-12 years to the occurrence of dysmenorrhoea at age 15-16 years within the Amsterdam Born Children and their Development (ABCD) study?
DESIGN: Data of 1038 female adolescents were used. Participants' baseline characteristics were obtained using self-reported questionnaires up to the age of 11-12 years, as well as the obstetric information of their mothers during pregnancy. Dysmenorrhoea was assessed at the age of 15-16 years, and was deemed to be present if an adolescent reported menstrual abdominal and/or back pain and therefore took medication and/or hormonal contraception. Using a backward selection approach, potential determinants of dysmenorrhoea were selected and multivariable associations were determined.
RESULTS: The overall prevalence of dysmenorrhoea was 49.5% among the participants. Intake of 3-4.5 sugar-sweetened beverages/day (P = 0.035) and higher gynaecological age (i.e. years since menarche) (P < 0.001) were significantly associated with higher occurrence of dysmenorrhoea in the final model, which explained 8.1% of the total variance in the occurrence of dysmenorrhoea. No significant associations were found between the occurrence of dysmenorrhoea and sociodemographic or psychosocial factors.
CONCLUSIONS: This investigation of various potential risk factors for dysmenorrhoea suggests that diet and reproductive factors are particularly important predictors of the occurrence of dysmenorrhoea among young adolescents. Specifically, intake of sugar-sweetened beverages and higher gynaecological age were predictive of the occurrence of dysmenorrhoea. Other lifestyle factors were also identified as possible risk factors. Using this knowledge, effective strategies can be developed to reduce the burden of dysmenorrhoea among adolescents, and to provide appropriate care for those suffering from the condition.
The invention belongs to the technical field of foot bath Chinese herbal medicines, and discloses a composition for aiding sleep and soothing nerves, a preparation method and application thereof. The product for assisting sleep and soothing nerves adopts a traditional Chinese medicine preparation, the compatibility of medicines follows the concept of diagnosis and treatment based on traditional Chinese medicine, the product is prepared by applying a modern process, the using method is external application, the use is convenient and fast, the effect is obvious, the price is low, the safety is high, the effect is obvious, the reason for sleep disorder can be fundamentally adjusted, and the product has great advantage for adjusting sleep disorder. The caulis spatholobi, cortex albiziae and poria with hostwood are used as monarch drugs, so that the blood is promoted and enriched, and the insomnia is treated; cortex Albizziae is effective in nourishing heart and relieving depression; poria with hostwood tranquilizes; the three medicines are monarch medicines together, so that the spirit nourishing and the sleep aiding are realized. Caesalpinia sappan is used as a ministerial drug for soothing the nerves and calming the mind. The angelica is used as an adjuvant drug for enriching and activating blood. The medulla Junci and cortex Phellodendri are used as guiding drugs to harmonize the properties of the drugs. The sleep-aiding and nerve-soothing foot bath bag/liquid has the main function of solving the problems of difficulty in falling asleep, poor sleep quality and other sleep disorders.
Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes. Pain intensity and vital signs will be evaluated and recorded before each application and in the first five minutes after the application.
Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
Sulconazole nitrate has been shown to be embryotoxic in rats when given in doses 125 times the human dose (in mg/kg). The drug at this dose given orally to rats also resulted in prolonged gestation and dystocia. Several females died during the perinatal period, most likely due to labor complications. Sulconazole nitrate was not teratogenic in rats or rabbits at oral doses of 50 mg/kg/day. 

There are no adequate and well-controlled studies in pregnant women. Sulconazole nitrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The presence of calcifications, which is a relatively common feature in intrathoracic lymph nodes, typically contributes to confer them a heterogeneous aspect during endosonographic B-mode examination, but a possible association between calcifications and metastatic involvement has never been systematically evaluated. The most likely reason why this possible association has been overlooked up to now is that the presence of calcifications in intrathoracic lymph nodes has long been thought to be the consequence of the prior involvement from granulomatous diseases (i.e., tuberculosis or sarcoidosis), and as such has been considered a sign of benignity. However, the presence of lymph node calcifications at ultrasound examination is a known predictor of lymph node metastasis in patients with some specific tumours, such as the papillary thyroid carcinoma or the squamous cell carcinoma of head or neck. Furthermore, recent radiological-pathological studies have shown that metastatic foci from lung cancer are observed in up to 19% calcified mediastinal lymph nodes identified at CT in surgical candidates. Finally, a recently published EBUS study has reported, for the first time, a very strong association between a very specific pattern of mediastinal lymph node calcification, known as "starry sky sign", and metastasis from pulmonary, colonic and breast adenocarcinoma. Interestingly, the starry sky sign is characterized by the presence of few to countless dot-like calcifications which are too small to be seen at CT and can be identified only during EBUS B-mode examination.

To the best of our knowledge, no studies have been carried out to assess the correlation between the presence and the ultrasound pattern of lymph node calcifications and lymph node metastasis from lung cancer or other intrathoracic malignancies.
1344042 Dentifrice preparation COLGATEPALMOLIVE CO 16 March 1972 [22 March 1971] 12404/72 Heading A5B A dentifrice is prepared by (a) mixing a water-soluble salt of 1, 6-di (p-chlorophenylbiguanido) hexane, an alkali metal salt of a carboxyalkylcellulose, a humectant, a surface active agent and water in such a way that the di(chlorophenylbiguanido) hexane salt and the carboxyalkylcellulose salt only come into contact in the presence of the surface active agent and (b) adding to this mixture a water-insoluble dental polishing agent. The di(chlorophenylbiguanido) hexane salt may be the digluconate. The carboxyalkylcellulose salt may be sodium carboxymethylcellulose. The humectant may be glycerol, sorbitol propylene glycol or poly(ethylene glycol). The surface active agent may be sodium N-lauroyl sarcosinate. The polishing agent may be colloidal silica, an alkali metal aluminosilicate, dicalcium orthophosphate dihydrate, or calcium carbonate. The composition may also include sodium saccharine, calcium chloride and/or oil of peppermint. The di(chlorophenyl biguanido) hexane salt may be added to the carboxyalkyl cellulose salt either simultaneously with or after the surface active agent.
Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30-minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and bi-weekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
The invention discloses a product for detecting liver cancer or liver cancer prognosis based on a PRSS35 pathway and a liver cancer treatment medicament based on a PRSS35 pathway. The product comprises a detection substance of PRSS35 gene or PRSS35 protein. The detection substance is one of a primer pair for specifically amplifying PRSS35 gene, a reagent for specifically identifying PRSS35 protein and a reagent for specifically binding PRSS35 protein. The invention discovers that the expression of PRSS35 in liver cancer tumor in vivo is obviously reduced in comparison with the expression in normal liver tissue; the protein level of PRSS35 in the serum of the patient with liver cancer is also obviously reduced compared with that of the normal person. Exogenous overexpression of PRSS35 in mouse liver significantly slowed the progression of mice to induce liver cancer. Based on the above, the PRSS35 pathway molecule can be a tumor auxiliary diagnosis marker, can be an effective target for tumor treatment, and can also be a survival prognosis index of a liver cancer patient.
The participants in this group will receive no training and they can participate in the social VR training after the intervention period. To ensure the consistency of the experiment, the participants are not allowed to initiate or change their pharmacological treatment during the 3-week intervention period.
PROBLEM TO BE SOLVED: To obtain a safe and effective carcinogenesis suppressing agent especially useful for suppressing the crisis of gastrointestinal cancer. SOLUTION: This agent contains 1-70wt.%, preferably 5-50wt.% (based on total composition) of a carbostyril derivative of the formula (R is a halogen) or its salt as an active component. It can properly be compounded with conventional diluent, excipient, etc., and formed in the form of peroral drug, suppository, injection, aerosol, syrup or external agent. The agent may be compounded to a resin, etc., to improve the sustained release property. The daily administration dose of the compound is preferably 0.6-50mg per 1kg body-weight. The administration unit preferably contains 10-100mg of the active component. The agent is effective for the treatment of cancers of skin, tongue, pharynx, bronchi, esophagus, stomach, duodenum, small intestine, large intestine, etc. The compound of formula is e.g. 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid.
FIELD: medicine. SUBSTANCE: invention relates to use of chitosan and polysaccharide fixed on it. Polysaccharide is taken among heparin, heparan sulfate, chondroitin sulfates and dextran sulfate as agent providing the stimulated regeneration of solid tissue. Invention relates to also method of stimulation and/or acceleration of solid tissue regeneration by applying the indicated agent on corresponding tissue site. The third object of invention is the implant for integration into solid tissue. At least part of implant designated for integration is covered with indicated agent. Invention provides stimulation of solid tissue cells growth, formation of regenerated osseous tissue being mainly laminar, compact type. EFFECT: enhanced effectiveness of agent. 20 cl, 13 ex
Glossopharyngeal neuralgia (GPN) is an unusual disorder causing severe, brief pain episodes in the areas supplied by the glossopharyngeal nerve. Initial treatment involves medications like carbamazepine, but if these are ineffective or cause side effects, interventional pain management techniques or surgery may be considered. Gamma Knife radiosurgery is becoming popular in managing GPN due to its lower risk of complications than surgical interventions like microvascular decompression or rhizotomy. In this retrospective case series, we examined the outcomes of Gamma Knife radiosurgery in eight patients with GPN. The decision to utilize Gamma Knife radiosurgery was made following specific criteria, including failed surgical interventions, patient preference against surgery, or contraindications to surgical procedures. Patients were administered radiation doses within the range of 80 to 90 Gy, targeting either the cisternal glossopharyngeal nerve or glossopharyngeal meatus of the jugular foramen. Evaluations were conducted before the Gamma Knife radiosurgery; at 3, 6, and 12 months after Gamma Knife radiosurgery; and annually thereafter. Pain severity was assessed using the modified Barrow Neurological Institute scale grades, with patients achieving grade I-IIIa considered to have a good treatment outcome and grade IV-V to have a poor treatment outcome. Pain control and absence of radiosurgery-related complications were primary endpoints. The median age of the patients was 46.5 years, varying from 8 to 72 years. The median duration of pain was 32 months (range, 12-120 months). All patients, except one, were on polydrug therapy. All cases exhibited preoperative grade V pain. The median follow-up duration after Gamma Knife radiosurgery was 54.5 months, varying from 14 to 90 months. The overall clinical assessments revealed a gradual neurological improvement, particularly within the first 8.5 weeks (range, 1-12 weeks). The immediate outcomes at 3 months revealed that all patients (8/8, 100%) experienced pain relief, with 25% (2/8) achieving a medication-free status (Grade I). Three patients (37%) experienced a recurrence during the follow-up and were managed with repeat Gamma Knife radiosurgery (n = 2) and radiofrequency rhizotomy (n = 1). At the last follow-up, 88% (7/8) of patients had pain relief (Grades I-IIIa), with three (37%) achieving a medication-free status (Grade I). No adverse events or neurological complications occurred. The patient who underwent radiofrequency rhizotomy continued to experience inadequately controlled pain despite medication (Grade IV). Gamma Knife radiosurgery is a non-invasive, efficacious treatment option for idiopathic GPN, offering short- and long-term relief without permanent complications.
Early nutritional and growth experiences can impact development, metabolic function, and reproductive outcomes in adulthood, influencing health trajectories in the next generation. The insulin-like growth factor (IGF) axis regulates growth, metabolism, and energetic investment, but whether it plays a role in the pathway linking maternal experience with offspring prenatal development is unclear. To test this, we investigated patterns of maternal developmental weight gain (a proxy of early nutrition), young adult energy stores, age, and parity as predictors of biomarkers of the pregnancy IGF axis (n = 36) using data from the Cebu Longitudinal Health and Nutrition Survey in Metro Cebu, Philippines. We analyzed maternal conditional weight measures at 2, 8, and 22 years of age and leptin at age 22 (a marker of body fat/energy stores) in relation to free IGF-1 and IGFBP-3 in mid/late pregnancy (mean age = 27). Maternal IGF axis measures were also assessed as predictors of offspring fetal growth. Maternal age, parity, and age 22 leptin were associated with pregnancy free IGF-1, offspring birth weight, and offspring skinfold thickness. We find that free IGF-1 levels in pregnancy are more closely related to nutritional status in early adulthood than to preadult developmental nutrition and demonstrate significant effects of young adult leptin on offspring fetal fat mass deposition. We suggest that the previously documented finding that maternal developmental nutrition predicts offspring birth size likely operates through pathways other than the maternal IGF axis, which reflects more recent energy status.
PURPOSE: To enable correct billing, product inquiry, and total minimum expense bearing by providing a central computer means, a communication means for automatic processing of order alteration of prescription, a decentralized calculating means, and a manual terminal means. CONSTITUTION: An order is received by a personal computer(PC) 111 at a clinic. A telephone exchange system 104 receives its data and inputs the data to a central computer 101 through a terminal interface 103 and a PC 102. This PC-to- PC ordering makes easy the prescription by a doctor based upon all relative lens parameters. The computer 101 is connected to terminals (company) 106 and 107 having a primary stock input function and a primary distribution control function. A printer 109 generates a shipping label 122 and a relative document 120 according to prepared orders. Shifts between input systems 102 and 104, and stock input and withdrawal 106 and 107 are batch mode reports and a procedure exampled by a printer 108, a report 120, and a form 121 is generated.
PURPOSE: To obtain a composition having an effect for treating a cycle of hair and its functional damage, inducement and stimulation of formation of the hair and reduction of loss of the hair by combining a calcium antagonist with a pyrimidine derivative. CONSTITUTION: This composition is obtained by combining (A) the first component containing 0.01-10% at least one calcium antagonist (e.g. the one selected from papaverine derivative, 1,4-dihydropyridine derivative, benzothiazepine derivative) in a pharmaceutically permissible medium, with (B) the second component containing O. 05-10 %, especially 0. 54 % pyrimidine derivative of formula I (R. is a group of formula II; R3 and R4 are each H, alkyl, etc.; R2 is H, alkyl, alkynyl, etc.) or its salt of a pharmaceutically permissible acid in a pharmaceutically permissible medium. The combined medicine is administered as a single composition containing both components (containing preparation just before the administration) or as both individual components simultaneously or successively.
The invention discloses a notoginsenoside processed product and a preparation method and application thereof. Dissolving Notoginseng radix total saponin with water, placing in a hydration reaction kettle, controlling temperature at 120 deg.C, and reacting for 27 hr. Cooling the reaction solution, performing column chromatography separation, concentrating, and drying to obtain the desired notoginsenoside processed product. The obtained processed product contains 8 monomer components including 20(S) -Rh1, 20(R) -Rh1, Rk3, Rh4, 20(S) -Rg3, 20(R) -Rg3, Rk1 and Rg 5. The notoginsenoside processed product has obvious effects of losing weight and reducing blood fat, and can be used as a raw material for developing medicaments for losing weight, reducing blood fat and the like. Meanwhile, the processed product of the notoginsenoside also has good application prospect in preparing health care products or foods for losing weight and reducing blood lipid.
All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, whereas the participants in the "control group" kept on sitting quietly without legs soaking during the additional 20-minute period.
Therapeutic oral composns. comprising ribonuclease and another antiinflammatory enzyme in an enteric-coated capsule, the enzymes being incorporated in a water-soluble base contg. polyoxyethyleneglycol as lubricant are used for treatment of inflammation without fear of protein shock which may accompany parenteral treatment. Other enzymes include trypsin, chymotrypsin, ficin, bromelains, amylase, papain. The preferred diluent for ribonuclease and chymotrypsin is lactose and the preferred lubricant is a polyoxyethylene glycol of 4000-6000 mol. wt.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in children and adolescents. NAFLD ranges in severity from isolated hepatic steatosis to nonalcoholic steatohepatitis (NASH), wherein hepatocellular inflammation and/or fibrosis coexist with steatosis. Circulating microRNA (miRNA) levels have been suggested to be altered in NAFLD, but the extent to which miRNA are related to NAFLD features remains unknown. This analysis tested the hypothesis that plasma miRNAs are significantly associated with histological features of NAFLD in adolescents.
AIM: To investigate the relationship between plasma miRNA expression and NAFLD features among adolescents with NAFLD.
METHODS: This study included 81 adolescents diagnosed with NAFLD and 54 adolescents without NAFLD from the Teen-Longitudinal Assessment of Bariatric Surgery study. Intra-operative core liver biopsies were collected from participants and used to characterize histological features of NAFLD. Plasma samples were collected during surgery for miRNA profiling. A total of 843 plasma miRNAs were profiled using the HTG EdgeSeq platform. We examined associations of plasma miRNAs and NAFLD features using logistic regression after adjusting for age, sex, race, and other key covariates. Ingenuity Pathways Analysis was used to identify biological functions of miRNAs that were associated with multiple histological features of NAFLD.
RESULTS: We identified 16 upregulated plasma miRNAs, including miR-193a-5p and miR-193b-5p, and 22 downregulated plasma miRNAs, including miR-1282 and miR-6734-5p, in adolescents with NAFLD. Moreover, 52, 16, 15, and 9 plasma miRNAs were associated with NASH, fibrosis, ballooning degeneration, and lobular inflammation, respectively. Collectively, 16 miRNAs were associated with two or more histological features of NAFLD. Among those miRNAs, miR-411-5p was downregulated in NASH, ballooning, and fibrosis, while miR-122-5p, miR-1343-5p, miR-193a-5p, miR-193b-5p, and miR-7845-5p were consistently and positively associated with all histological features of NAFLD. Pathway analysis revealed that most common pathways of miRNAs associated with multiple NAFLD features have been associated with tumor progression, while we also identified linkages between miR-122-5p and hepatitis C virus and between miR-199b-5p and chronic hepatitis B.
CONCLUSION: Plasma miRNAs were associated with NAFLD features in adolescent with severe obesity. Larger studies with more heterogeneous NAFLD phenotypes are needed to evaluate miRNAs as potential biomarkers of NAFLD.